# Immuno-neural mechanisms in gastrointestinal tumorigenesis: bridging inflammation, neural regulation, and therapeutic innovation

## TL;DR

This paper explores how immune and neural interactions contribute to gastrointestinal cancer and suggests new treatment strategies targeting these mechanisms.

## Contribution

The paper introduces the concept of targeting immuno-neural axes for improved gastrointestinal cancer treatment.

## Key findings

- Chronic inflammation and neural signaling pathways contribute to gastrointestinal tumor progression.
- Colorectal cancer stem cells use neuronal signaling for self-renewal.
- Combining immune and neural-targeted therapies may improve cancer treatment outcomes.

## Abstract

Gastrointestinal (GI) tumors remain a leading cause of global cancer mortality, with late-stage diagnosis and metastatic dissemination posing major clinical challenges. This review synthesizes current understanding of the intricate interplay between immune regulation, neural signaling, and tumor microenvironment dynamics in GI malignancies. We highlight how chronic inflammation, driven by pathogens like H. pylori or inflammatory bowel disease, establishes a pro-tumorigenic milieu through cytokine networks (IL-1β, TNF-α, IL-6) and Wnt/β-catenin signaling, while neural components (serotonergic, cholinergic, and peptidergic pathways) actively participate in cancer progression via neurotrophic factors and neurotransmitter-mediated crosstalk. Emerging evidence reveals that colorectal cancer stem cells exploit neuronal signaling (particularly 5-HT/Wnt activation) for self-renewal, and that perineural invasion serves as a critical metastatic route. The dual role of immune cells is explored, with macrophages (M1/M2 polarization), T cells, and neutrophils exhibiting both tumor-suppressive and pro-metastatic functions depending on context. We evaluate recent therapeutic advances including immune checkpoint inhibitors, CAR T-cell therapies, and neural-targeted approaches, while addressing limitations such as chemoresistance and immune-related adverse events. The potential of microbiota modulation and nanotechnology for precision therapy is discussed. By integrating molecular mechanisms with clinical observations, this work proposes that combinatorial strategies targeting immuno-neural axes may overcome current treatment barriers, emphasizing the need for early detection and personalized approaches in GI oncology.